Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-A00464-35 | Other Identifier | ID-RCB number, ANSM | |
| PRME-15-0464 | Other Identifier | DGOS number, PRME number |
Not provided
Not provided
insufficiency inclusion during the inclusion periode
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Health, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The main objective of the present study is to describe the quality of life of patients under 25 years of age with pediatric-onset IBD. The quality of life will be described according to the age and the activity of the disease in order to make it possible to associate with the different states of health a measure of quality of life (utility score) from utility values established in the French context. These data are essential for the realization of medico-economic models.
The continuous increase in incidence of chronic inflammatory bowel disease (IBD) will increase their burden on health care costs in the future. Pediatric IBD is frequently associated with an aggressive phenotype causing specific complications (undernutrition, pubertal delay or height-weight loss) and has a long-term impact on quality of life.
Therapeutic evolutions were marked in the 1990s by the arrival of immunosuppressants and then in the 2000s of biotherapies (anti-TNF).To limit the accumulation of tissue damage and to benefit from the maximum effectiveness of anti -TNF, clinicians are tempted to offer early treatment of CD with anti-TNF.
An ongoing study using data from the EPIMAD registry aims to study the impact of therapies on the disease course of patients with IBD in their childhood (Inspired study). This study also contains a medico-economic component, the objective of which is to evaluate the cost-effectiveness of the different management strategies for pediatric onset IBD. As part of this economic study, quality of life data will be needed. Indeed, there are very few data on quality of life in children / adolescents with IBD in the literature. These data must be collected from patients, unlike the other data used (retrospective data, in medical records).
The main objective of the present study is to describe the quality of life of patients under 25 years of age with pediatric-onset IBD. The quality of life will be described according to the age and the activity of the disease in order to make it possible to associate with the different states of health a measure of quality of life (utility score) from utility values established in the French context. These data are essential for the realization of medico-economic models.
This study will supplement data currently being collected from patients over 25 years of age, quality of life being the subject of a secondary objective of a study on the professional integration of patients with IBD (PROMICI study , ID-RCB: 2017-A03397-46).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life according to age and disease activity | Quality of life is measured by EQ5D-5L questionnaire and transformed into utility according to French reference values | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between EQ5D-5L and SIBDQ questionnaire in adults | EQ5D-5L is a generic measure of quality of life and SIBDQ a disease-specific questionnaire of quality of life | through study completion, an average of 1 year |
| Correlation between EQ5D-5L and IMPACT III questionnaire in adolescents |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with pediatric-onset IBD (diagnosed before the age of 17) and aged over 12 and under 25 at the time of the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dominique TURCK | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hop Jeanne de Flandre Chu Lille | Lille | 59037 | France |
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
EQ5D-5L is a generic measure of quality of life and IMPACT III a disease-specific questionnaire of quality of life |
| through study completion, an average of 1 year |
| Quality of life according to previous surgery occurence | Quality of life is measured by EQ5D-5L | through study completion, an average of 1 year |
| Correlation between quality of life and perceived health | Quality of life measured by EQ5D-5L and perceived health by Visual Analogue Scale | through study completion, an average of 1 year |
| Quality of life according to profession and academic degree (adults only) | Quality of life as measured by EQ5D-5L | through study completion, an average of 1 year |
| Quality of life according to profession and academic degree (adults only) | Quality of life as measured by SIBDQ | through study completion, an average of 1 year |
| D007410 | Intestinal Diseases |
| D003092 | Colitis |
| D003108 | Colonic Diseases |